TCGA-CV-A6JY-01A-11R-A31N-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.370
- MYC_TARGETS_V2+0.340
- CHOLESTEROL_HOMEOSTASIS+0.200
- BILE_ACID_METABOLISM+0.180
- FATTY_ACID_METABOLISM+0.160
- MYC_TARGETS_V1+0.160
- ADIPOGENESIS+0.150
- MTORC1_SIGNALING+0.140
- ESTROGEN_RESPONSE_EARLY+0.130
- P53_PATHWAY+0.120
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.620
- ANGIOGENESIS-0.500
- INTERFERON_ALPHA_RESPONSE-0.500
- INTERFERON_GAMMA_RESPONSE-0.450
- ALLOGRAFT_REJECTION-0.440
- INFLAMMATORY_RESPONSE-0.380
- COAGULATION-0.360
- E2F_TARGETS-0.350
- MYOGENESIS-0.320
- COMPLEMENT-0.300
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | X08d41e55.6d66.4e03.9dc3.3743f3da0453 | — | cohortA2 | 0.868 |
| 2 | X265fd2ee.a8d9.4142.bf96.86a40f37234e | — | cohortA2 | 0.854 |
| 3 | 1e409782-57e3-42ab-8952-678a4cdb6b2f | — | — | 0.847 |
| 4 | SRR6013506 | — | cohortA2 | 0.843 |
| 5 | ULC1533T_S61 | — | cohortA2 | 0.838 |
| 6 | ERR2278863 | — | — | 0.836 |
| 7 | SRR8518209 | — | C | 0.834 |
| 8 | TCGA-TN-A7HJ-01A-12R-A34R-07 | — | — | 0.832 |
| 9 | 37b95452-c6ab-48f9-abd4-521b33596657 | — | — | 0.823 |
| 10 | ERR2278860 | — | — | 0.823 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.370 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.340 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| BILE_ACID_METABOLISM | 0.180 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.160 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.160 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.150 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.140 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.130 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.120 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.120 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.110 | Idelalisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| PROTEIN_SECRETION | 0.110 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.100 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.100 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.090 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.080 | Remibrutinib | — uncovered |
| PEROXISOME | 0.080 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |